Free tool
FAERS Monitor: Merilog
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761325 or its brand name (Merilog, Insulin Aspart-Szjj). Reports on generic versions are filed under their own applications.
Reports
10
Serious
2
20% of reports
Hospitalization
2
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2
- off label use2
- blood glucose abnormal1
- blood glucose increased1
- hyperhidrosis1
- hyperthyroidism1
- hypoglycaemia1
- hypoglycaemic coma1
- incorrect route of product administration1
- intentional overdose1
- intentional product misuse1
- loss of consciousness1
- poor quality product administered1
- product dispensing error1
- product dispensing issue1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 2 |
| 2026 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,149 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypoglycaemic coma | 1 | 730.0 | 113.7 | 181 |
| product dispensing issue | 1 | 491.8 | 76.6 | 122 |
| poor quality product administered | 1 | 199.6 | 31.1 | 49 |
| hyperthyroidism | 1 | 145.3 | 22.6 | 35 |
| incorrect route of product administration | 1 | 122.7 | 19.1 | 30 |
| blood glucose abnormal | 1 | 113.9 | 17.7 | 28 |
| product dispensing error | 1 | 96.6 | 15.0 | 23 |
| hypoglycaemia | 1 | 43.4 | 6.8 | 10 |
| intentional overdose | 1 | 32.8 | 5.1 | 7 |
| intentional product misuse | 1 | 24.0 | 3.7 | 5 |
| loss of consciousness | 1 | 16.4 | 2.6 | 3 |
| hyperhidrosis | 1 | 16.3 | 2.5 | 3 |
| blood glucose increased | 1 | 11.2 | 1.7 | 2 |
| off label use | 2 | 4.8 | 1.4 | 3 |
| drug ineffective | 2 | 3.2 | 0.9 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.